Details for Patent: 8,258,132
✉ Email this page to a colleague
Which drugs does patent 8,258,132 protect, and when does it expire?
Patent 8,258,132 protects EMEND and is included in two NDAs.
This patent has forty-eight patent family members in thirty-seven countries.
Summary for Patent: 8,258,132
| Title: | Pharmaceutical composition of a tachykinin receptor antagonist |
| Abstract: | The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phen- yl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis. |
| Inventor(s): | Bosch; H. William (Bryn Mawr, PA), Liversidge; Elaine (West Chester, PA), Shelukar; Suhas D. (Lansdale, PA), Thompson; Karen C. (Lansdale, PA) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 10/317,948 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Use; |
Drugs Protected by US Patent 8,258,132
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-003 | Jun 30, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING | ⤷ Sign Up | |||
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-003 | Jun 30, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY | ⤷ Sign Up | |||
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-001 | Mar 26, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY | ⤷ Sign Up | ||
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-001 | Mar 26, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING | ⤷ Sign Up | ||
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-002 | Mar 26, 2003 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING | ⤷ Sign Up | ||
| Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-002 | Mar 26, 2003 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY | ⤷ Sign Up | ||
| Msd Merck Co | EMEND | aprepitant | FOR SUSPENSION;ORAL | 207865-001 | Dec 17, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV) | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,258,132
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 037713 | ⤷ Sign Up | |||
| Austria | 400254 | ⤷ Sign Up | |||
| Australia | 2002360824 | ⤷ Sign Up | |||
| Brazil | 0214786 | ⤷ Sign Up | |||
| Brazil | PI0214786 | ⤷ Sign Up | |||
| Canada | 2469315 | ⤷ Sign Up | |||
| China | 100352443 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
